UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

(Mark One)

⊠ (QUARTERLY REPORT PURSUANT TO SECTION 13 OF	R 15(d) OF THE SECURITIES EXC	HANGE ACT OF 1934
F	or the quarterly period ended June 30, 2023		
□ T	TRANSITION REPORT PURSUANT TO SECTION 13 OF	R 15(d) OF THE SECURITIES EXC	HANGE ACT OF 1934
F	or the transition period from to		
		Commission File No. 3	33-188920
		ODYSIGHT.	ALINC
		(Exact name of registrant as spe	
	Nevada		47-4257143
	(State or other jurisdiction		(I.R.S. Employer
	of incorporation or organization)		Identification No.)
	Suite 7A, Industrial Park		
	P.O. Box 3030, Omer, Israel	_	8496500
	(Address of Principal Executive Office	s)	(Zip Code)
		+972 73 370-46	
		(Registrant's telephone number,	including area code)
	(Former	name, former address and former fisca	vear if changed since last report)
	•	name, remer address and remer rised	Tyen, it changes there has reporty
Secur	ities registered pursuant to Section 12(b) of the Act:		
	Title of each class	Trading Symbol(s)	Name of exchange on which registered
	N/A	N/A	N/A
	tte by check mark whether the registrant (1) has filed all reporter period that the registrant was required to file such reports), a		or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for su quirements for the past 90 days. Yes \boxtimes No \square
	ate by check mark whether the registrant has submitted electro eceding 12 months (or for such shorter period that the registra		ired to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) duries \boxtimes No \square
	ate by check mark whether the registrant is a large accelerated rge accelerated filer," "accelerated filer," "smaller reporting co		rated filer, a smaller reporting company, or an emerging growth company. See the definitiony" in Rule 12b-2 of the Exchange Act.
	Large accelerated filer		Accelerated filer
\boxtimes	Non-accelerated filer		Smaller reporting company
			Emerging growth company
	emerging growth company, indicate by check mark if the regled pursuant to Section 13(a) of the Exchange Act. \Box	gistrant has elected not to use the exte	nded transition period for complying with any new or revised financial accounting standar
Indica	ate by check mark whether the registrant is a shell company (as	defined in Rule 12b-2 of the Exchange	Act). Yes □ No ⊠
As of	August 13, 2023, the registrant had 10,436,684 shares of com-	mon stock, par value \$0.001 of the regis	trant issued and outstanding.
	ed in this Quarterly Report and unless otherwise indicated, vise specified, all dollar amounts are expressed in United State		wn as ScoutCam Inc.)," "we," "us," "our," or "our Company" refer to Odysight.ai. Unle

ODYSIGHT.AI INC.

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

		Page
Cautionary	y Note Regarding Forward-Looking Statements	3
DADT 1 E	FINANCIAL INFORMATION	
PAKI 1-F	TRANCIAL INFORMATION	
Item 1.	Consolidated Financial Statements (unaudited)	4
	Consolidated Balance Sheets	5
	Consolidated Statements of Comprehensive Loss	7
	Statements of Stockholders' Equity	8
	Consolidated Statements of Cash Flows	10
	Notes to Consolidated Financial Statements	12
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	25
Item 4.	Control and Procedures	25
PART II-0	OTHER INFORMATION	
Item 1A.	Risk Factors	26
Item 6.	<u>Exhibits</u>	26
SIGNATU	<u>ires</u>	27
	-2-	

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere herein may address or relate to future events and expectations and as such constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2022 (filed on March 28, 2023) entitled "Risk Factors" as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

Item 1. Financial Statements

ODYSIGHT.AI INC. (Formerly known as ScoutCam Inc.)

INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2023

CONSOLIDATED ODYSIGHT.AI INC.

	Page
Interim Condensed Consolidated Financial Statements - in US Dollars (USD) in thousands	
Interim Condensed Consolidated Balance Sheets (unaudited)	5
Interim Condensed Consolidated Statements of Operations (unaudited)	7
Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited)	8
Interim Condensed Consolidated Statements of Cash Flows (unaudited)	10
Notes to the Interim Condensed Consolidated Financial Statements	12
-4-	

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2023	December 31, 2022
	Unaudited	Audited
	USD in tho	isands
Assets		
CURRENT ASSETS:		
Cash and cash equivalents	3,319	10,099
Short terms deposits	18,736	3,047
Accounts receivable	158	60
Inventory	724	630
Other current assets	668	281
	23,605	14,117
NON-CURRENT ASSETS:		
Contract fulfillment assets	1,376	1,495
Property and equipment, net	513	648
Operating lease right-of-use assets	653	307
Severance pay asset	262	328
	2,804	2,778
TOTAL ASSETS	26,409	16,895

 $The accompanying \ notes \ are \ an \ integral \ part \ of \ these \ interim \ condensed \ consolidated \ financial \ statements.$

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

	June 30, 2023	December 31, 2022
	Unaudited	Audited
	USD in tho	usands
Liabilities and shareholders' equity		
CURRENT LIABILITIES:		
	774	297
Accounts payable Contract liabilities - short term	774 954	1,426
	232	1,426
Operating lease liabilities - short term		
Accrued compensation expenses	454 47	365 58
Related parties		
Other account payable	522	214
	2,983	2,559
NON-CURRENT LIABILITIES:		
Contract liabilities - long term	2,007	2,218
Operating lease liabilities - long term	339	64
Liability for severance pay	256	268
Other liabilities - long term	28	-
	2,630	2,550
TOTAL LIABILITIES	5,613	5,109
	3,013	3,107
SHAREHOLDERS' EQUITY:		
Common stock, \$0.001 par value; 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022,		
10,436,684 and 7,121,737 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively	10	7
Additional paid-in capital	51,110	36,541
Accumulated deficit	(30,324)	(24,762)
TOTAL SHAREHOLDERS' EQUITY	20,796	11,786
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	26,409	16,895

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Six months ended	June 30,	Three months ended June 30,					
	2023	2022	2023	2022				
		Unaudite	1					
		USD in thousands (except per share data)						
REVENUES	977	372	674	370				
COST OF REVENUES	1,327	849	777	561				
GROSS LOSS	(350)	(477)	(103)	(191)				
RESEARCH AND DEVELOPMENT EXPENSES	2,753	1,975	1,355	1,021				
SALES AND MARKETING EXPENSES	669	446	493	203				
GENERAL AND ADMINISTRATIVE EXPENSES	2,126	2,452	1,168	1,166				
OPERATING LOSS	(5,898)	(5,350)	(3,119)	(2,581)				
OTHER INCOME	10	15	3	7				
FINANCING INCOME (EXPENSES), NET	326	(225)	240	(198)				
NET LOSS	(5,562)	(5,560)	(2,876)	(2,772)				
Net loss per ordinary share (basic and diluted, USD)	(0.63)	(0.78)	(0.28)	(0.39)				
Weighted average ordinary shares (basic and diluted, in thousands)	8,864	7.122	10,435	7,122				

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

Six Months Ended June 30, 2023 (Unaudited)

	Comm	on Sto	ck		Additional paid-in	A	ccumulated	Si	Total nareholders'
	Number		Amount		capital		deficit		equity
	In thousands		USD in thousands			ls			
Balance at January 1, 2023	7,122	\$	7	\$	36,541	\$	(24,762)	\$	11,786
Stock based compensation	-		-		685		-		685
Issuance of shares upon RSU vesting	21		*		*		-		-
Issuance of shares and warrants	3,294		3		13,884		-		13,887
Net loss			<u> </u>				(5,562)		(5,562)
Balance at June 30, 2023	10,437	\$	10	\$	51,110	\$	(30,324)	\$	20,796

Three Months Ended June 30, 2023 (Unaudited)

				Additional				Total
	Ordina	ry shai	res	paid-in	Ac	cumulated	Sha	areholders'
	Number		Amount	capital		deficit		Equity
	In thousands		_	USD in thousands				
Balance at April 1, 2023	10,433	\$	10	\$ 50,813	\$	(27,448)	\$	23,375
Stock based compensation	-		-	337		-		337
Issuance of shares upon RSU vesting	4		*	*		-		-
Issuance expenses	-		-	(40)		-		(40)
Net loss	<u>-</u> _		<u> </u>	<u>-</u>		(2,876)		(2,876)
Balance at June 30, 2023	10,437	\$	10	\$ 51,110	\$	(30,324)	\$	20,796

^{*} Represents an amount less than \$1 thousand

Six Months Ended June 30, 2022 (Unaudited)

	Ordinary	shares	Additional paid-in	Accumulated	Total Shareholders'
	Number Amount		capital deficit		Equity
	In thousands		USD in the	ousands	
Balance at January 1, 2022	7,122	7	34,903	(15,294)	19,616
Stock based compensation	-	-	1,457	-	1,457
Net loss	<u>-</u> _			(5,560)	(5,560)
Balance at June 30, 2022	7,122	7	36,360	(20,854)	15,513

Three Months Ended June 30, 2022 (Unaudited)

			Additional		Total
	Ordinary	shares	paid-in	Accumulated	Shareholders'
	Number Amount		capital	deficit	Equity
	In thousands		USD in the	ousands	
Balance at April 1, 2022	7,122	7	35,675	(18,082)	17,600
Stock based compensation	-	-	685	-	685
Net loss	-	-	-	(2,772)	(2,772)
Balance at June 30, 2022	7,122	7	36,360	(20,854)	15,513

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months ended	l June 30,	Three months end	ed June 30,
	2023	2022	2023	2022
		Unaudite	i	
		USD in thous	ands	
CASH FLOWS FROM OPERATING ACTIVITIES:				
Net loss	(5,562)	(5,560)	(2,876)	(2,772)
Adjustments to reconcile net loss to net cash used in operations:	``	``	1	
Depreciation	192	103	37	53
Stock based compensation	685	1,457	337	685
Severance pay asset and liability	54	51	-	51
Profit from exchange differences from operating lease liability	(22)	(50)	(13)	(40)
Loss from exchange differences on cash and cash equivalents	53	327	49	286
Interest income in respect of deposits	(189)	(23)	(231)	(10)
CHANGES IN OPERATING ASSET AND LIABILITY ITEMS:				
Increase in accounts receivable	(98)	(91)	(97)	(85)
Increase in inventory	(94)	(442)	(31)	(419)
Decrease (increase) in other current assets	(387)	33	(104)	6
Decrease in contract fulfillment assets	119	60	59	60
Decrease in ROU asset	94	132	50	113
Increase in account payables	477	206	409	82
Increase (decrease) in contract liabilities	(683)	1,435	(455)	(181)
Decrease in operating lease liability	(110)	(125)	(62)	(109)
Increase in accrued compensation expenses	89	21	152	1
Increase (decrease) in related parties	(11)	(17)	39	
Increase in other account payable	310	85	128	105
Net cash flows used in operating activities	(5,083)	(2,398)	(2,609)	(2,174)
CASH FLOWS FROM INVESTING ACTIVITIES:				
Purchase of property and equipment	(57)	(42)	(42)	(18)
Withdrawal of short terms deposits	3,000	5,000	-	5,000
Investment in short term deposits	(18,500)	(3,500)	(3,500)	(3,500)
Net cash flows provided by (used in) investing activities	(15,557)	1,458	(3,542)	1,482
CASH FLOWS FROM FINANCING ACTIVITIES:				_
Proceeds from issuance of shares and warrants	12.012		(CA)	
Net cash flows provided by used in financing activities	13,913		(64)	
Net cash flows provided by used in financing activities	13,913		(64)	
DECREASE IN CASH AND CASH EQUIVALENTS	(6,727)	(940)	(6,215)	(692)
LOSS FROM EXCHANGE DIFFERENCES ON CASH AND CASH				
EQUIVALENTS	(53)	(327)	(49)	(286)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE				
PERIOD	10,099	8,581	9,583	8,292
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE				
PERIOD	3,319	7,314	3,319	7,314

Non cash activities -

	Six months ended	June 30,	Three months ende	d June 30,		
	2023	2023 2022		2022		
	Unaudited					
		ands				
Unpaid issuance expenses	26	-	(24)			
Right-of-use assets obtained in exchange for operating lease liabilities	465	81	382	35		
Termination of right-of-use assets in exchange for cancellation of operating lease						
obligations	(25)	-	(25)			

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL:

a. Odysight.ai.Inc (the "Company"), formerly known as ScoutCam Inc., was incorporated under the laws of the State of Nevada on March 22, 2013. Prior to the closing of the Exchange Agreement (as defined below), the Company was a non-operating "shell company".

The Company's wholly owned subsidiary, Odysight.ai Ltd ("Odysight.ai".), formerly known as ScoutCam Ltd., was formed in the State of Israel on January 3, 2019, as a wholly-owned subsidiary of Medigus Ltd. ("Medigus"), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019.

In December 2019, Medigus and Odysight.ai consummated an asset transfer agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to Odysight.ai.

On December 30, 2019, the Company and Medigus consummated a securities exchange agreement (the "Exchange Agreement"), pursuant to which Medigus delivered 100% of its holdings in Odysight.ai to the Company in exchange for shares of the Company's common stock representing 60% of the issued and outstanding share capital of the Company immediately upon the consummation of the Exchange Agreement.

During 2020 - 2023 Medigus has decreased its holdings in the Company such that as of March 31, 2023, Medigus owned 18.45% of the Company's outstanding common stock.

On June 1, 2023, Medigus sold all its holdings in the Company to existing shareholders and to Chairman of the Board and CEO of the Company.

On June 5, 2023, the Company filed with the Nevada Secretary of State a Certificate of Amendment to the Registrant's Articles of Incorporation to change its name from "ScoutCam Inc." to "Odysight.ai Inc.", effective June 5, 2023.

The Company, through Odysight.ai, is engaged in the development, production and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries. Some of the Company's products utilize micro visualization technology in medical devices for minimally invasive medical procedures.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - GENERAL (continued):

b. Since incorporation of Odysight.ai and through June 30, 2023, the Company accumulated a deficit of approximately \$30.3 million and its activities have been funded mainly by its shareholders. The Company's management believes the Company' cash and cash resources will allow the Company to fund its operating plan through at least the next 12 months from the filing date of these Interim Condensed Consolidated Financial Statements. However, the Company expects to continue to incur significant research and development and other costs related to its ongoing operations, requiring the Company to obtain additional funding in order to continue its future operations until becoming profitable.

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

a. Unaudited Interim Financial Statements

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group's Annual Report on Form 10-K for the year ended December 31, 2022.

b. Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

c. Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock-based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued):

d. Significant Accounting Policies

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

e. Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group's condensed consolidated financial statements.

NOTE 3 - LEASES:

In December 2020, Odysight ai entered into a lease agreement for office space in Omer, Israel ("original space"), with the 36-month term for such agreement beginning on January 1, 2021. In March 2021, Odysight ai entered into a lease agreement for additional office space in Omer, Israel ("additional space"), with the term for such agreement is ending December 31, 2023.

On June 25, 2023, Odysight.ai entered into an amendment to these agreements, pursuant to which the lease for the additional office space will be shortened and end on June 30, 2023 and the lease for original space will be extended for an additional five years until December 31, 2028. It was also agreed that Odysight.ai has an option to terminate the agreement for the original space after three years.

Monthly lease payments under the agreement for the original space are approximately \$7 thousand.

In December 2022, Odysight.ai entered into a lease agreement for office space in Ramat Gan, Israel. The agreement is for 12 months beginning on December 14, 2022 and the Company has an option to extend the lease period for an additional one year. The Company does not expect to extend the lease period. Therefore, the Company has elected to use the practical expedient regarding short-term leases. Monthly lease payments under the agreement are \$3 thousand.

C:-- --- --- 41-- --- 41-4

Supplemental cash flow information related to operating leases was as follows:

	Six mont	Six months ended	
	June 30, 2023	June 30, 2022	
	USD in t	housands	
Cash paid for amounts included in the measurement of lease liabilities:			
Operating cash flows from operating leases	119	136	

As of June 30, 2023, the Company's operating leases had a weighted average remaining lease term of 0.9 years and a weighted average discount rate of 6%.

Future lease payments under operating leases as of June 30, 2023 were as follows:

	Operating leases
	USD in thousands
Remainder of 2023	120
2024	231
2025	188
2026	83
Total future lease payments	622
Less imputed interest	(51)
Total lease liability balance	571

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY:

a. Private Placement

On March 16, 2023, the Company consummated a Stock Purchase Agreements for a private placement with (i) Moshe Arkin through his individual retirement account and (ii) The Phoenix Insurance Company Ltd. and Shotfut Menayot Israel – Phoenix Amitim, in connection with the sale and issuance of an aggregated amount of 3,294,117 units (collectively, the "Units"), at a purchase price of \$4.25 per Unit, and for an aggregated purchase price of \$14,000,000. Each Unit consists of: (i) one share of the Company's common stock with par value of \$0.001 per share (the "Common Stock") and (ii) one warrant to purchase one share of Common Stock with an exercise price of \$5.50 (the "Warrants"). The Warrants are immediately exercisable and will expire three years from the date of issuance and will be subject to customary adjustments.

Warrants:

As of June 30, 2023, the Company had the following outstanding warrants to purchase common stock:

	Issuance	Expiration	Exercise Price Per Share	Number of Shares of common stock Underlying
Warrant	Date	Date	(\$)	Warrants
March 2021 Warrant	March 29, 2021	March 31, 2026	10.35	2,469,156
March 2023 Warrant	March 27, 2023	March 26, 2026	5.50	3,294,117
				5,763,273

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - EQUITY (continued):

b. Stock-based compensation to employees, directors and service providers:

In February 2020, the Company's Board of Directors approved the 2020 Share Incentive Plan (the "Plan").

The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company's Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 64,099 shares of common stock. On June 22, 2020, the Company's Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 777,778 shares of common stock. During the second quarter of 2021, the Company's Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 777,778 shares of common stock. During the first quarter of 2023, the Company's Board of Directors approved an increase to the option pool pursuant to the Plan by an additional 1,000,000 shares of common stock.

The Plan is designed to enable the Company to grant options to purchase shares of common stock and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3 (i) of the Israeli Tax Ordinance.

Stock option activity

During the six months ended June 30, 2023, the Company granted 57,000 options pursuant to the Plan.

The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:

	June 30, 2023
Underlying value of ordinary shares (\$)	5
Exercise price (\$)	4.5
Expected volatility (%)	37.5%
Term of the options (years)	7
Risk-free interest rate	3.94%

The cost of the benefit embodied in the options granted during the six months ended June 30, 2023, based on their fair value as of the grant date, is estimated to be approximately \$142 thousand. These amounts will be recognized in the statements of operations and comprehensive income over the vesting period.

The following table summarizes stock option activity for the six months ended June 30, 2023:

	For the Six months ended June 30, 2023	
	Amount of options	Weighted average exercise price
		\$
Outstanding at beginning of period	1,560,040	3.64
Granted	57,000	4.50
Fortfeited	(20,365)	3.47
Outstanding at end of period	1,596,675	3.68
Vested at end of period	978,486	3.11

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – EQUITY (continued):

Restricted stock unit ("RSU") activity

Each RSU will vest based on continued service which is generally over three years. The grant date fair value of the award will be recognized as stock-based compensation expense over the requisite service period. The fair value of restricted stock units was estimated on the date of grant based on the fair value of the Company's common stock.

The following table summarizes RSU activity for the three months ended June 30, 2023:

	Six month	For the Six months ended June 30, 2023	
	Amount of RSUs	Weighted Average Grant Date Fair Value per Share	
		\$	
Outstanding at beginning of period	50,000	6.32	
Vested	(20,830)	6.32	
Unvested and Outstanding at end of period	29,170	6.32	

The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operation and comprehensive income:

	Six months ended
	June 30, 2023
	USD in thousands
Cost of revenues	5
Research and development	265
Sales and marketing expenses	62
General and administrative	353
Total expenses	685

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5 – REVENUES:

Disaggregation of revenue

		Six months ended June 30, 2023	
	2023	2022	
	USD in the	USD in thousands	
Development Services (*)	211	106	
Products	766	266	
Revenue	977	372	

(*) During the second quarter of 2022, the Company completed the development of the product relating to a customer-specific project for a Fortune 500 multinational healthcare corporation and moved from the development phase of the project to its production phase. As a result, during the six months ended June 2023, the Company recognized development services revenues and related development costs that had been previously deferred, in the amount of \$211 thousand. The amount was recognized based on the expected manufacturing term of the product, which the Company estimates at seven years.

In addition, following the commencement of the production phase, the Company recognized product revenues of \$722 thousand during the six months ended June 2023 from the sale of units of the product developed in the context of these development services.

Contract fulfillment assets and Contract liabilities:

The Company's contract fulfillment assets and contract liabilities as of June 30, 2023 and December 31, 2022 were as follows:

	June 30,	December 31,
	2023	2022
	USD in	thousands
Contract fulfillment assets	1,376	1,495
Contract liabilities	2,961	3,644

Contract liabilities include advance payments, which are primarily related to advanced billings for development services.

The change in contract fulfillment assets:

	June 30,	December 31,	
	2023	2022	
	USD in th	ousands	
Balance at beginning of year	1,495	1,675	
Contract costs recognized during the period	(119)	(180)	
Balance at end of year	1,376	1,495	

The change in contract liabilities:

	June 30,	December 31,
	2023	2022
	USD in t	housands
Balance at beginning of year	3,644	2,420
Deferred revenue relating to new sales	-	1,613
Revenue recognized during the year	(683)	(389)
Balance at end of year	2,961	3,644

Remaining Performance Obligations

Remaining Performance Obligations ("RPO") represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of June 30, 2023, the total RPO amounted to \$2.9 million, which the Company expects to recognize over the expected manufacturing term of the product.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - INVENTORY:

Composed as follows:

	June 30, 2023	December 31, 2022
	USD in thousands	
Raw materials and supplies	563	438
Work in progress	42	148
Finished goods	119	44
	724	630

During the period ended June 30, 2023, no impairment occurred.

NOTE 7 – LOSS PER SHARE

Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares as described below.

In computing the Company's diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the dilutive effect, if any, of the Company's potential shares of common stock. The denominator for diluted loss per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.

NOTE 8 - RELATED PARTIES

a. Balances with related parties:

	June 30 , 2023	December 31, 2022
	USD in thousands	
Directors (directors' accrued compensation)	38	48
Smartec R&D Ltd. (see b below)	9	10
	47	58

b. During six months ended June 30, 2023 the Company received development services from Smartec R&D Ltd., a company owned by the Company's CTO.

Total compensation during the six months ended June 30, 2023 and June 30, 2022 were approximately \$29 thousands and \$55 thousands, respectively.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

The Company received approval from the Israel Innovation Authority (previously the Office of the Chief Scientist), (the "IIA") to support and enhance the Company's production line and capabilities in the next 12 months until May 2024. Pursuant to the agreement with the IIA relating to the program, the Company has to pay royalties of 3% to the IIA up to the amount IIA funding received and the accrued interest repayment of the grant is contingent upon the Company successfully completing its enhancement plans and generating sales from the enhancements preformed. The Company has no obligation to repay these grants if its enhancement plans are not completed or aborted or if it generates no sales. The Company had not yet started the enhancement plan as of June 30, 2023.

On June 12, 2023, the Company received an advance from the IIA in the amount of NIS 357 thousand (approximately \$96 thousand), which was recorded as a short term liability in the other account payable account, since the Company may need to repay this advance to IIA in case its enhancement plans will not be completed or aborted.

NOTE 10 – SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company identified no subsequent events as of the date that the financial statements were issued.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See "Cautionary Note Regarding Forward-Looking Statements". You should review the "Risk Factors" section of our Annual Report for the fiscal year ended December 31, 2022 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis:

Overview

Overview

The Company's primary business activities during last few months were:

- Production and supply of product to a Fortune 500 multinational healthcare corporation.
- Enlarging our focus on R&D activities in the domain of I4.0 (including PdM and CBM in sectors such as aerospace, maritime energy and other heavy machinery, engines and complicated mechanics which have a need for monitoring and predictive maintenance applications). The main effect of this activity was an increase in the number of employees to enable the Company to manage the anticipated increased workload and solution development activity.

Comparison of the Six months ended June, 2023 and 2022

The following table summarizes our results of operations for the six month period ended June 30, 2023 and 2022, together with the changes in those items in dollars and as a percentage:

	Six months ended June 30,		
	2023	2022	% Change
Revenues	977,000	372,000	163%
Cost of Revenues	1,327,000	849,000	56%
Gross Loss	(350,000)	(477,000)	(27)%
Research and development expenses	2,753,000	1,975,000	39%
Sales and marketing expense	669,000	446,000	50%
General and administrative expenses	2,126,000	2,452,000	(13)%
Operating Loss	(5,898,000)	(5,350,000)	10%

Revenues

As a result of the nature of our target market and the current stage of our development, a substantial portion of our revenue comes from a limited number of customers.

For the six months ended June 30, 2023, we generated revenues of \$977,000, an increase of \$605,000, or 163%, compared to revenues of \$372,000 for the six months ended June 30, 2022.

The increase in revenues was primarily due to the completion of development of the product relating to our miniature camera solution with a Fortune 500 company during the second quarter of 2022 and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company for the six months ended June 30, 2023 amounted to approximately \$933,000 compared to \$327,000 for the six months ended June 30, 2022.

Cost of Revenues

Cost of revenue is primarily comprised of cost of personnel including warehouse personnel costs, certain allocated facilities, and expenses associated with logistics and quality control.

Cost of revenues for the six months ended June 30, 2023 was \$1,327,000, an increase of \$478,000, or 56%, compared to cost of revenues of \$849,000 for the six months ended June 30, 2022.

The increase was primarily due to an increase in material costs due to an increase in the number of products sold and supplied to the Fortune 500 company.

Gross Loss

Gross loss for the six months ended June 30, 2023 was \$350,000, a decrease of \$127,000, or 27%, compared to gross loss of \$477,000 for the six months ended June 30, 2022.

The decrease was primarily due to increase in revenues partially offset by increase in cost of revenues, as described above.

Research and Development Expenses

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting, and professional fees related to research and development activities, prototype materials, facility costs, and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies. We expense research and development costs as incurred.

Research and development expenses for the six months ended June 30, 2023 were \$2,753,000, an increase of \$778,000, or 39%, compared to \$1,975,000 for the six months ended June 30, 2022.

The increase was primarily due to an increase in payroll expenses from additional employee recruitments, as result of enlarging our focus on R&D activities in the domain of 14.0.

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the 14.0 domain.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of payroll expenses, consulting services, promotional materials, exhibitions ,demonstration equipment, and certain allocated facility infrastructure costs

Sales and marketing expenses for the six months ended June 30, 2023 were \$669,000, an increase of \$223,000, or 50%, compared to \$446,000 for the six months ended June 30, 2022.

The increase was primarily due to recent rebranding activities (including expenses related to the changing of the name of the Company which include among other designing a new logo and promotional materials). In addition, during June 2023 the Company participated on Paris Air Show, the world's premier and largest event dedicated to the aviation and space industry.

This increase was partially offset by a decrease in payroll expenses (including stock-based compensation) due to the resignation of our VP Business Development during the fourth quarter of 2022.

We expect that our selling and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services, and insurance costs.

General and administrative expenses for the six months ended June 30, 2023 were \$2,126,000, a decrease of \$326,000, or 13%, compared to \$2,452,000 for the six months ended June 30, 2022.

The decrease was primarily due to stock-based compensation vesting of options and to a decrease in D&O insurance costs.

Operating loss

We incurred an operating loss of \$5,898,000 for the six months ended June 30, 2023, an increase of \$548,000, compared to operating loss of \$5,350,000 for the six months ended June 30, 2022.

The increase in operating loss was primarily due to an increase in expenses related to research and development and sales and marketing expenses, partially offset by a decrease in general and administrative expenses, each as described above.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):

	Six month end	Six month ended June 30,	
	2023	2022	
Cash used in Operating Activity	(5,083,000)	(2,398,000)	
Cash provided by (used in) Investing Activity	(15,557,000)	1,458,000	
Cash provided by Financing Activity	13,913,000	-	

Operating Activities

Our primary uses of cash from operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. We expect that our cash flows from operating activities will continue to increase due to an expected increase of expenses of our business and our working capital requirements.

During the six months ended June 30, 2023, cash used in operating activities was \$5.1 million, consisting of net loss of \$5.5 million, an unfavorable net change in operating assets and liabilities of \$0.3 million, partially offset by a non-cash benefit of \$0.8 million. Our non-cash benefit consisted primarily of non-cash charges for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash outflows from changes in contract liability and other current assets, was partially offset by inflows from changes in account payables and other accounts payables.

During the six months ended June 30, 2022, cash used in operating activities was \$2.4 million, consisting of net loss of \$5.6 million, partially offset by a non-cash benefit of \$1.5 million, a favorable net change in operating assets and liabilities of \$1.3 million and loss from exchange differences on cash and cash equivalents of \$0.3 million. Our non-cash benefit consisted primarily of non-cash charges of \$1.5 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in contract liability of \$1.4 million.

Investing Activities

During the six months ended June 30, 2023, cash used in investing activities was \$15.6 million, consisting mainly of investment, net on short-term deposits.

For the six months ended June 30, 2022, net cash flows provided by investing activities was \$1.5 million consisting mainly of withdrawal of short terms deposits.

Financing Activities

During the six months ended June 30, 2023, cash provided by financing activities was \$13.9 million, consisting of cash proceeds from issuance of shares and warrants, net of issuance costs.

Comparison of the three months ended June 30, 2023 and 2022

The following table summarizes our results of operations for the three months period ended June 30, 2023, and 2022, together with the changes in those items in dollars and as a percentage:

	Three months en	ded June 30,		
	2023	2022	% Change	
Revenues	674,000	370,000	82%	
Cost of Revenues	777,000	561,000	39%	
Gross Loss	(103,000)	(191,000)	(46)%	
Research and development expenses	1,355,000	1,021,000	33%	
Sales and marketing expense	493,000	203,000	143%	
General and administrative expenses	1,168,000	1,166,000	-%	
Operating Loss	(3,119,000)	(2,581,000)	21%	

Revenues

For the three months ended June 30, 2023, we generated revenues of \$674,000, an increase of \$304,000, or 82%, from the three months ended June 30, 2022.

The increase in revenues was primarily due to the completion of development of the product relating to our miniature camera solution with a Fortune 500 company and moving to production stage. Total revenues recorded from our miniature camera solution with the Fortune 500 company for the three months ended June 30, 2023 amounted to approximately \$645,000, compared to \$327,000 for the three months ended June 30, 2022.

Cost of Revenues

Cost of revenue is primarily comprised of cost of personnel including warehouse personnel costs, certain allocated facilities, and expenses associated with logistics and quality control.

Cost of revenues for the three months ended June 30, 2023 was \$777,000, an increase of \$216,000, or 39%, compared to cost of revenues of \$561,000 for the three months ended June 30, 2022.

The increase was primarily due to an increase in material costs due to an increase in the number of products sold and supplied to the Fortune 500 company.

Gross Loss

Gross loss for the three months ended June 30, 2023 was \$103,000, a decrease of \$88,000, or 46%, compared to gross loss of \$191,000 for the three months ended June 30, 2022.

The decrease was primarily due to increase in revenues partially offset by increase in cost of revenues, both as described above.

Research and Development Expenses

Research and development efforts are focused on new product development and on developing additional functionality for our new and existing products. These expenses primarily consist of employee-related expenses, including salaries, benefits, and stock-based compensation expense for personnel engaged in research and development functions, consulting, and professional fees related to research and development activities, prototype materials, facility costs, and other allocated expenses, which include expenses for rent and maintenance of our facility, utilities, depreciation, and other supplies. We expense research and development costs as incurred.

Research and development expenses for the three months ended June 30, 2023 were \$1,355,000, an increase of \$334,000, or 33%, compared to \$1,021,000 for the three months ended June 30, 2022.

The increase was primarily due to an increase in payroll expenses from additional employee recruitments, as result of enlarging our focus on R&D activities in the domain of 14.0.

We expect that our research and development expenses will increase as we continue to develop our products and service and recruit additional research and development employees to the I4.0 domain.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of payroll expenses, consulting services, promotional materials, exhibitions ,demonstration equipment, and certain allocated facility infrastructure costs.

Sales and marketing expenses for the three months ended June 30, 2023 were \$493,000, an increase of \$290,000, or 143%, compared to \$203,000 for the three months ended June 30, 2022.

The increase was primarily due to recent rebranding activities (including mainly expenses related to the changing of the name of the Company which include among other designing a new logo and promotional materials). In addition, during June 2023 the Company participated in the Paris Air Show, the world's premier and largest event dedicated to the aviation and space industry.

We expect that our selling and marketing expenses will increase as we expand our selling and marketing efforts in the I4.0 domain.

General and Administrative Expenses

General and administrative expenses primarily consist of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor, public relations, accounting, auditing, tax services, and insurance costs.

General and administrative expenses for the three months ended June 30, 2023 were \$1,168,000, an increase of \$2,000, compared to \$1,166,000 for the three months ended June 30, 2022.

Operating loss

We incurred an operating loss of \$3,119,000 for the three months ended June 30, 2023, an increase of \$538,000, compared to operating loss of \$2,581,000 for the three months ended June 30, 2022.

The increase in operating loss was primarily due to increases in expenses related to research and development and sales and marketing expenses.

Cash Flows

The following table sets forth the significant sources and uses of cash for the periods set forth below (in dollars):

	I nree month end	I firee month ended June 30,	
	2023	2022	
Cash used in Operating Activity	(2,609,000)	(2,174,000)	
Cash provided by (used in) Investing Activity	(3,542,000)	1,482,000	
Cash used in Financing Activity	(64,000)	-	

Operating Activities

Our primary use of cash from operating activities have been for payroll expenses, research and development costs, manufacturing costs, marketing and promotional expenses, professional services cost and costs related to our facilities. We expect that our cash flows from operating activities will continue to be increase due to the expected increase in spending on our business and our working capital requirements.

During the three months ended June 30, 2023, cash used in operating activities was \$2.6 million, consisting of net loss of \$2.9 million, a favorable net change in operating assets and liabilities of \$0.1 million and a non-cash benefit of \$0.2 million. Our non-cash benefit consisted primarily of non-cash charges of \$0.3 million for stock-based compensation.

During the three months ended June 30, 2022, cash used in operating activities was \$2.2 million, consisting of net loss of \$2.8 million and an unfavorable net change in operating assets and liabilities of \$0.4 million partially offset by a non-cash benefit of \$0.7 million, and loss from exchange differences on cash and cash equivalents of \$0.3 million. Our non-cash benefit consisted primarily of non-cash charges of \$0.7 million for stock-based compensation. The net change in our operating assets and liabilities primarily reflects cash inflows from changes in inventory of \$0.4 million.

Investing Activities

For the three months ended June 30, 2023, net cash flows used in investing activities was \$3.5 million, consisting mainly of investment, net on short-term deposits.

For the three months ended June 30, 2022, net cash flows provided by investing activities was \$1.5 million consisting mainly of withdrawal of short terms deposits.

Financing Activities

For the three months ended June 30, 2023, net cash flows used in financing activities was \$64,000, consisting of issuance expenses.

Liquidity and Capital Resources

As of June 30, 2023, we had cash and cash equivalents of \$3.3 million and \$18.7 million of short-term deposits compared to cash and cash equivalents \$10.1 million and \$3.0 million of short-term deposits as of December 31, 2022. In addition, as of June 30, 2023 we incurred an accumulated deficit of approximately \$30.3 million, compared to \$24.8 million as of December 31, 2022.

Our primary sources of liquidity to date have been from fund raisings and warrant exercises

Additional Cash Requirements

We plan to continue to invest for long-term growth, and therefore we expect that our expenses will increase. We currently believe that our existing cash and cash equivalents and short-term deposits, as of August 14, 2023, will allow us to fund our operating plan through at least the next 12 months. We expect our expenses will increase in connection with our ongoing activities, particularly as we continue the research and development and the scale up process of our 14.0 solutions. We expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. Furthermore, we will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We may raise these funds through equity financing, or other sources, which may result in further dilution in the equity ownership of our common stock. There is no assurance that we will be able to maintain operations at a level sufficient for investors to obtain a return on their investment in our common stock, or that we will be able to raise sufficient capital required to implement our business plan on acceptable terms, if at all. Even if we are successful in raising sufficient capital to implement our business plan, we will, most likely, continue to be unprofitable for the foreseeable future. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information requested by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Exchange Act Rule 13a-15(e). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

No change in our internal control over financial reporting, as defined in Exchange Act Rule 13a-15(e), occurred during the fiscal quarter ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.

ITEM 1A. RISK FACTORS.

There have been no material changes from the information set forth in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31,2022 as filed with the SEC on March 28, 2023.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

There have been no unregistered sales of equity securities in addition to the sales provided under Form 8-K as filed with the SEC during the recent fiscal quarter ended June 30, 2023.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS.

(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.

Exhibit

Number	Description
3.1.1	Amended and Restarted Articles of Incorporation, effective as of June 4,2023 (incorporated by reference to Exhibit 3.1.1 to our Registration Statement on Form S-1 filed with the SEC on July 17, 2023)
3.2.1	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.1 to our Registration Statement on Form S-1 filed with the SEC on July 17, 2023)
31.1*	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
31.2*	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
32.1**	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	Inline XBRL Instance Document
101.INS	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
*	Filed herewith.
**	Furnished herewith.
	-26-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2023

ODYSIGHT.AI INC

By: Name: Title:

/s/ Yehu Ofer Yehu Ofer Chief Executive Officer Odysight.ai.Inc

/s/ Tanya Yosef
Tanya Yosef
Chief Financial Officer
Odysight.ai.Inc By: Name: Title:

CERTIFICATION PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Yehu Ofer, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023 of Odysight.ai.Inc.
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the quarter end covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the quarter end presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the quarter end in which this report is being prepared;
- b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the quarter end covered by this report based on such evaluation; and
- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2023

/s/ Yehu Ofer

Chief Executive Officer
(Principal Executive Officer)

CERTIFICATION PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Tanya Yosef, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2023, of Odysight.ai.Inc.
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the quarter end covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the quarter end presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the quarter end in which this report is being prepared;
- b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the quarter end covered by this report based on such evaluation; and
- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 14, 2023

/s/ Tanya Yosef

Tanya Yosef
Chief Financial Officer
(Principal Financial Officer)

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Odysight.ai.Inc. (the "Company") on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Yehu Ofer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Yehu Ofer Yehu Ofer Chief Executive Officer

(Principal Executive Officer) August 14, 2023

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Odysight.ai.Inc. (the "Company") on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Tanya Yosef, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Tanya Yosef Tanya Yosef Chief Financial Officer (Principal Financial Officer) August 14, 2023